Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific for the development and manufacturing of ARCT-032, its investigational mRNA therapeutic for cystic fibrosis. Under the Master Services Agreement, Thermo Fisher will provide up to $40 million in clinical manufacturing services, while Arcturus will engage Thermo Fisher's PPD for up to $40 million in CRO services. This partnership aims to support Phase 3 development and potential commercialization, with Thermo Fisher gaining exclusive commercial manufacturing rights upon regulatory approval.

Arcturus Therapeutics reported a significant decline in its first quarter 2026 financial results, with total revenue plummeting 93% to $2.1 million compared to $29.4 million in the prior year. The company's net loss widened to $27.0 million, or $0.95 per share, from a net loss of $14.1 million, or $0.52 per share, in Q1 2025. This was primarily driven by a sharp decrease in collaboration revenue. As of March 31, 2026, cash and cash equivalents stood at $211.4 million.

Arcturus Therapeutics announced the appointment of Dennis Mulroy as Chief Financial Officer, effective May 1, 2026, strengthening its executive team. The company reported a net loss of $27.0 million for Q1 2026, an increase from $14.1 million in Q1 2025, with total revenue decreasing to $2.1 million from $29.4 million year-over-year. Despite the financial results, Arcturus highlighted pipeline progress, including initiating enrollment for its ARCT-032 cystic fibrosis Phase 2 study and receiving a clear FDA path for its ARCT-810 OTC deficiency program, while maintaining a cash runway beyond Q2 2028.

Arcturus Therapeutics Holdings Inc. filed a definitive proxy statement (DEF 14A) announcing its 2026 Annual Meeting of Stockholders. The virtual meeting is scheduled for June 5, 2026, at 9:00 a.m. Pacific Time. Stockholders will vote on the election of eight directors, a non-binding advisory resolution on named executive officer compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026. The record date for voting is April 14, 2026.